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Abstract
To establish a genetic tool for conditional deletion or expression of gene in neurons in a temporally controlled manner, we
generated a transgenic mouse (NSE-MerCreMer), which expressed a tamoxifen inducible type of Cre recombinase specifically
in neurons. The tamoxifen inducible Cre recombinase (MerCreMer) is a fusion protein containing Cre recombinase with two
modified estrogen receptor ligand binding domains at both ends, and is driven by the neural-specific rat neural specific
enolase (NSE) promoter. A total of two transgenic lines were established, and expression of MerCreMer in neurons of the
central and enteric nervous systems was confirmed. Transcript of MerCreMer was detected in several non-neural tissues such
as heart, liver, and kidney in these lines. In the background of the Cre reporter mouse strain Rosa26R, Cre recombinase
activity was inducible in neurons of adult NSE-MerCreMer mice treated with tamoxifen by intragastric gavage, but not in
those fed with corn oil only. We conclude that NSE-MerCreMer lines will be useful for studying gene functions in neurons for
the conditions that Cre-mediated recombination resulting in embryonic lethality, which precludes investigation of gene
functions in neurons through later stages of development and in adult.
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Introduction
Conventional gene knockout in mice can result in early lethality,
which prevents study of gene functions through later stages of
development and in adult. To circumvent early lethality, the use of
Cre/loxP system to generate conditional gene deletion in a spatial
and temporal manner has become the most popular method. Cre
recombinase is a Type I topoisomerase from bacteriophage P1
that catalyzes the site-specific recombination of DNA between loxP
elements in both bacteriophage and mammalian cells [1,2,3]. The
loxP recognition element is a 34 base pair (bp) DNA sequence
comprised of two 13 bp inverted repeats flanking an 8 bp spacer
region which confers directionality [4]. Cre recombination could
result in excision, inversion or translocation of the floxed (flanked
with two loxP sites) genomic regions depending on the locations
and orientations of the loxP elements [3,5]. By utilization of a
specific promoter driving a spatially restricted Cre expression,
conditional deletion of a gene or activation of transgene expression
can be achieved in specific tissue in mice, thus offering the
opportunity to study gene function with spatial control [3,6]. A
further refinement of the Cre/loxP technology is the development
of inducible Cre transgene which permits temporal control of gene
recombination, allowing investigation of gene functions in a
particular developmental stage of the entire life-span of mice.
The inducible Cre recombinase is consisted of mutated ligand-
binding domain (LBD) of the mouse estrogen or progesterone
receptor and Cre recombinase [3,7,8]. The mutated LBD fails to
bind to estrogen or progesterone, but retains its ability in binding
to synthetic ligands such as tamoxifen, 4-OHT (4-hydroxy-
tamoxifen) and RU486 [3,7,9]. When ligand is absent, LBD-Cre
is bound by HSP90 and retained in the cytoplasm. Upon ligand
binding, LBD-Cre translocates into the nucleus and mediates
genomic recombination [3,7,9,10]. Therefore, Cre-mediated
recombination is induced by the administration of synthetic
ligand, allowing a temporal control of the recombination event
[3,11]. The tamoxifen inducible Cre recombinase protein
(MerCreMer) is composed of (i) Cre recombinase (Cre) and (ii)
two tamoxifen-binding domains (Mer) of mutated mouse estrogen
receptor a (ERa), one at each end of the Cre recombinase,
ensuring efficient binding of MerCreMer to tamoxifen and 4-
OHT, but at the same time retaining maximal Cre activity [9].
Neural specific enolase (NSE) is a glycolytic enzyme enolase
abundantly but specifically expressed in terminally differentiated
neurons and neuroendocrine cells [12]. Transcript of mouse NSE
was detectable from E12 onwards [13], and its expression was
correlated with synaptogenesis [12,14]. The 1.8 kb rat NSE
promoter DNA fragment has been shown to drive expression of
target genes in brain neurons of the transgenic mice
[13,15,16,17,18,19]. A NSE-Cre mouse line has been previously
generated which exhibited spatially restricted Cre activity in
neurons of the central nervous system [18]. However, such mouse
line did not allow temporal control of Cre recombination.
In this study, we generated transgenic mouse line (NSE-
MerCreMer) that expressed tamoxifen inducible Cre activity in
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35799neurons. We cloned the rat NSE promoter 59 to the cDNA
encoding the MerCreMer and generated transgenic mouse lines that
expressed tamoxifen inducible Cre activity in neurons. RT-PCR,
Western blot analysis, immuno-histochemistry for MerCreMer were
performed to investigate the temporal and spatial expression
patterns of MerCreMer in different transgenic lines. Furthermore,
we crossed our mouse lines to reporter mice Rosa26R (R26R) [20].
Immuno-staining for b-galactosidase in NSE-MerCreMer/R26R
mice showed that Cre activity in neurons of the central and
enteric nervous systems was induced by tamoxifen.
Results and Discussion
Establishment of NSE-MerCreMer Transgenic Mice
Transgenic construct NSE-MerCreMer was constructed by linking
the rat NSE promoter 59 upstream of the cDNA encoding the
tamoxifen inducible Cre recombinase (MerCreMer), which is
composed of Cre recombinase and mutated ligand-binding
domain (LBD) of the mouse estrogen receptor a (ERa) (Mer) on
both ends (Figure 1). MerCreMer will only translocate into the
nucleus and mediate genomic recombination in the presence of
synthetic ligands such as tamoxifen and 4-OHT [3,7,9,10]. To
ascertain the tamoxifen induction of Cre activity of NSE-
MerCreMer, the transgenic construct was co-transfected together
with the pCAG-CAT-LacZ plasmid into HeLa cells. The pCAG-
CAT-LacZ plasmid carries a LacZ (b-galactosidase) gene downstream
of a chicken beta-actin promoter (CAG) and a ‘DNA stuffer’ (CAT)
flanked by two loxP sequences, so that LacZ is expressed only when
the DNA stuffer is removed by the action of Cre recombinase.
Addition of 4-OHT (0.8 mM; +OHT) induced a robust expression
of b-galactosidase of the co-transfected cells. In contrast, no b-
galactosidase could be detected in co-transfected cells without 4-
OHT treatment (2OHT) (Figure 1). These data indicated that
Cre activity was successfully induced in HeLa cells transfected with
the NSE-MerCreMer and the pCAG-CAT-LacZ vectors upon
treatment with 4-OHT.
To generate transgenic mice that express Cre recombinase in
neurons, NSE-MerCreMer was micro-injected into fertilized eggs. A
total of 54 mice were born from the micro-injection, and six
transgenic founders (4 males and 2 females) were identified by
PCR genotyping (Figure 1B). All the six founders transmitted the
transgene through germ-line, and 6 transgenic lines were
established (Table 1). Brain and intestine contain neurons of the
central nervous system (CNS) and the enteric nervous system
(ENS), respectively. Therefore, brain and intestine were collected
from the F3 transgenic mice (postnatal week-4) of each line, and
expression of the transgene was analyzed by RT-PCR and
Western blot. Transcript of MerCreMer was detected in four
transgenic lines by RT-PCR (Figure 1C). Expression of MerCre-
Mer protein in transgenic mice was further confirmed by Western
blot using the monoclonal anti-body (anti-ERa), which recognized
the ligand binding domain of the estrogen receptor a. Therefore,
anti-ERa could recognize both the endogenous ERa and the
mutated ERa ligand binding domain in MerCreMer. As shown in
Figure 1D, strong bands were detected in uterus and intestine,
corresponding to endogenous ERa (67 kDa) and MerCreMer
protein (113 kDa), respectively in two transgenic lines (#778,
#805). A very weak band (corresponding to 113 kDa) was also
observed in brain of mice in transgenic lines (#778, #805) upon
prolonged exposure (data not shown). However, MerCreMer
protein expression was not detected in the intestine and brain of
the other 2 transgenic lines that were found expressing the
MerCreMer transcript by RT-PCR (date not shown).
Figure 1. Generation of NSE-MerCreMer transgenic lines. A,
Transgenic construct NSE-MerCreMer consists of a 1.8 kb rat NSE gene
promoter and the cDNA encoding the tamoxifen inducible Cre
recombinase (MerCreMer). X-gal staining of NSE-MerCreMer and pCAG-
CAT-LacZ co-transfected HeLa cells with (+OHT) or without (2OHT) the
addition of synthetic ligand 4-OHT. B, PCR amplification of NSE-
MerCreMer transgene using CreR1 and CreF1 primer pair generated a
374 bp DNA fragment from genomic DNA of NSE-MerCreMer transgenic
mice (Tg) but not from non-transgenic mice (NTg). ‘+ve’ denotes PCR
amplification using the transgenic construct as template DNA. C, RT-
PCR analysis showed expression of the transgene (MerCreMer) in the
brain (Br, +RT) and intestine (I, +RT) of transgenic mouse. RT-PCR for
mouse b-actin (b-actin) was included to check the integrity of the RNA.
Reverse transcriptase was omitted in the first strand cDNA synthesis
which served as a negative control (2RT) to ascertain the PCR product
was not amplified from genomic DNA. D, Western blot analysis using
anti-body against ligand binding domain of estrogen receptor a (ERa)
detected a protein band of MerCreMer (113 kDa) in the intestine (I), and
a protein band of ERa (67 kDa) in the uterus (U) of transgenic mouse.
Abbreviation: M, DNA size marker.
doi:10.1371/journal.pone.0035799.g001
Table 1. Statistics of the generation of NSE-MerCreMer
transgenic mice.
Number of mice born 54
Number of founders (% transgenesis) 6 (11.1%) (4=;2 R)
Germ-line transmission (% transmission) 6/6 (100%)
Transgene expression
a 4/6 (RT-PCR); 2/6 (WB)
a, Number of transgenic lines showing expression of transgene in brain and
intestine as detected by RT-PCR or Western blot (WB).
doi:10.1371/journal.pone.0035799.t001
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nervous system (ENS) of the intestine in transgenic mice (from
lines #778 and #805) was investigated by immuno-fluorescence
using anti-bodies against estrogen receptor a (ERa) and Tuj1
(neuron marker). Immuno-reactivity of Tuj1 (green) was localized
to the neurons and nerve fiber of the ENS of transgenic and non-
transgenic intestines (Figure 2C, D and data not shown). Immuno-
reactivity of ERa (red) was detectable at the myenteric ganglion
plexus between the circular and the longitudinal muscle layers of
the intestine of transgenic mice (Figure 2F). Furthermore, ERa
immuno-reactivity was localized to the cytoplasm overlapping with
that of neuron marker Tuj1 (Figure 2H) in transgenic intestine,
indicating the cytoplasmic expression of MerCreMer in neurons.
The absence of ERa immuno-reactivity in non-transgenic control
Figure 2. Localization of MerCreMer protein to the enteric neurons in the intestine of NSE-MerCreMer transgenic mice. Immuno-
reactivity for Tuj1 (green; neuronal marker) was localized to the enteric ganglion plexus at the myenteric region between the circular muscle and the
longitudinal muscle of the intestine of non-transgenic mice (C), and transgenic mice (D). In contrast, immuno-reactivity for ERa (red) was only
detected at the myenteric plexus in the intestine of transgenic mice (F), but not in non-transgenic mice (E). Superimposed photos of immuno-
fluorescence for ERa (red) and Tuj1 (green) of transgenic intestine (H), and non-transgenic intestine (G) showed co-localization of ERa and Tuj1
immuno-reactivity in transgenic intestine. Dotted regions are magnified and showed as insets. Abbreviations: m, mucosa; cm, circular muscle; lm,
longitudinal muscle.
doi:10.1371/journal.pone.0035799.g002
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for the detection of MerCreMer transgenic protein in the
transgenic intestine.
Temporal and Spatial Expression of MerCreMer in NSE-
MerCreMer Mice
RT-PCR analysis was performed on RNAs isolated from
various tissues of postnatal week-4 transgenic mice to investigate if
MerCreMer transcript was expressed in other tissues besides the
central and the enteric nervous systems. High level expression of
MerCreMer was observed in the brain and intestine of transgenic
mice, nevertheless, weak to moderate expressions of MerCreMer
transgene were detectable in the heart and liver of transgenic mice
from line #778; and in the heart, liver and kidney of mice from
line #805 (Figure 3A). In line with low level expression of
transgene in non-neural tissues as observed in our transgenic mice,
the same NSE promoter has been previously shown to direct weak
level of transgene expression in non-neural tissues [13,15,16,18].
In mouse brain, neurogenesis occurs from E12 to E17 [21,22].
In mouse intestine, ENS progenitor cells migrate along the gut,
proliferate and differentiate into neurons and glia between E10.5
and E14.5 [23]. The expression of MerCreMer in brain and
intestine of transgenic embryos between E12.5 and E16.5 was
evaluated by RT-PCR to determine if the onset of the NSE-
MerCreMer expression matched with the neurogenesis of the CNS
and ENS in embryonic stages. The earliest detectable expression
of MerCreMer transcript in brain and intestine was at E14.5 for
transgenic line #778 (Figure 3B), which correlated with the
neurogenesis of CNS and ENS. However, for transgenic line
#805, expression of MerCreMer in brain and intestine was not
detectable till E16.5 (Figure 3B). Transcript of mouse endogenous
NSE was detectable from E12 onwards [13] and its expression was
correlated with synaptogenesis [12,14]. However, the same NSE
promoter has been shown to direct transgene expression in the
embryonic brain as early as E9.5 [16]. The variations in the
embryonic onset of transgene expression among different trans-
genic lines could be attributable to the (i) influences of the genetic
loci at which the transgene integrated in different transgenic lines,
and/or (ii) number of copies of the transgene integrated into the
genome.
Tamoxifen Inducible Cre Recombinase Activity in
Neurons
NSE-MerCreMer transgenic mice (from lines #778 and #805)
were crossed with Rosa26R Cre-dependent lacZ reporter mice
(R26R) (Soriano, 1999) to generate transgenic mice carrying both
the NSE-MerCreMer and R26R transgenic loci (NSE-MerCreMer/
R26R). Double transgenic mice (postnatal week-4) were divided
Figure 3. Spatial and temporal expression of transgene in NSE-MerCreMer mice. Total RNA was isolated from neural and non-neural tissues
from postnatal week-4 transgenic mice (A) or brain and intestine of transgenic embryos of various embryonic stages (B) from lines #778 and #805.
Expression of the transgene (NSE-MerCreMer) was analyzed by RT-PCR. RT-PCR for mouse b-actin (b-actin) was included to check the integrity of the
isolated RNA. Reverse transcriptase was omitted in the first strand cDNA synthesis which served as a negative control (-RT) to ascertain the PCR
product was not amplified from genomic DNA. Abbreviations: Br, brain; I, intestine; H, heart; Li, liver; Sp, spleen; Lu, lung; Ki, kidney.
doi:10.1371/journal.pone.0035799.g003
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experimental group, mice were given tamoxifen via intragastric
gavage for 4 consecutive days. Corn oil was given to mice in the
control group. Mice of both groups were sacrificed 3 days after the
last administration, brain and intestine were processed to assay the
tamoxifen inducible Cre activity in neurons of NSE-MerCreMer/
R26R transgenic adults by Western blot analysis and immuno-
histochemistry for b-galactosidase (Figure 4).
As shown in Figure 5, Western blot analysis with anti-b-
galactosidase serum demonstrated the presence of b-galactosidase
in the brain, spinal cord and small intestine of NSE-MerCreMer/
R26R transgenic mice only after tamoxifen induction, but b-
galactosidase was not detected in these tissues of the corn oil
controls. A weak expression of b-galactosidase was detected in the
brain of R26R mice, which indicated a low level of leaky
expression of the b-galactosidase from the Rosa26R locus.
Spatial expression of b-galactosidase in the brain of tamoxifen
treated NSE-MerCreMer/R26R double transgenic mice from both
transgenic lines was investigated by co-immuno-fluorescence using
anti-sera for b-galactosidase and NeuN (neuronal marker). Corn
oil treated NSE-MerCreMer/R26R mice and R26R mice were
included as controls to ascertain the specificity of the Cre-
mediated induction of b-galactosidase upon tamoxifen adminis-
tration in NSE-MerCreMer/R26R mice. Coronal sections from the
forebrain, rostral and caudal midbrain, and cerebellum of NSE-
Figure 4. Schematic diagram of transgenic mice crossing and tamoxifen induction of Cre activity. MerCreMer protein in the cytoplasm of
the neurons of NSE-MerCreMer/R26R mice moves into the nucleus after binding to tamoxifen, mediates the excision of the DNA stuffer. The LacZ gene
is transcribed. NSE-MerCreMer mice were crossed to Rosa26R reporter mice (R26R) to generate NSE-MerCreMer/R26R double transgenic mice.
Tamoxifen or corn oil was administered to postnatal week-4 double transgenic mice at day 1, 2, 3 and 4. Brain and intestine were harvested at day 7,
and processed for Western blot analysis and immuno-fluorescence staining for b-galactosidase.
doi:10.1371/journal.pone.0035799.g004
Figure 5. Tamoxifen induction of b-galactosidase in the central
nervous system and the intestine of NSE-MerCreMer/R26R mice.
Western blot analysis of protein extracted from the brain (Br), spinal
cord (SC) and small intestine (SI) of NSE-MerCreMer/R26R mice treated
with tamoxifen (TM) or corn oil (CO); Rosa26R mice (R26R) and Z/EG
mice. Except for the small intestine of Z/EG mice that 20 mg of protein
was loaded, 100 mg of protein was analyzed for all the other samples.
doi:10.1371/journal.pone.0035799.g005
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corn oil treated; at least two mice from each line were analyzed in
different treatment groups) and R26R mice were co-immuno-
stained for b-galactosidase (green) and NeuN (red). In tamoxifen
treated NSE-MerCreMer/R26R mice from both lines, majority of
the neurons (NeuN immuno-positive; red) at various regions of the
cerebral cortex from the forebrain (Figure 6A), rostral (Figure 6B)
and caudal midbrain (Figure 6C) were also immuno-positive for b-
galactosidase. In addition, neurons at the hippocampus, thalamus
and hypothalamus were also immuno-positive for b-galactosidase
in these tamoxifen treated NSE-MerCreMer/R26R mice. In corn oil
treated NSE-MerCreMer/R26R mouse brains, with the exception
that few neurons at the forebrain cerebral cortex of line #805
expressed very low level of b-galactosidase (arrows; Figure 6A),
neurons at all the other regions of the brain were not immuno-
reactive for b-galactosidase. No b-galactosidase immuno-reactivity
was detectable in all the brain sections of R26R mice (Figure 6A-
C). The weak expression of b-galactosidase in the forebrain
cerebral cortex of corn oil treated NSE-MerCreMer/R26R mice
from line #805 was probably attributed to low level of Cre activity
in the forebrain region of the mouse line #805. Purkinje cells in
the cortex of the cerebellum of the brain from the tamoxifen
treated NSE-MerCreMer/R26R mice from both lines were also
immuno-positive for b-galactosidase (arrowheads; Figure 6D). In
contrast, Purkinje cells in the cerebellum of corn oil treated NSE-
MerCreMer/R26R mice and R26R mice were not immuno-reactive
for b-galactosidase.
In the intestine, expression of b-galactosidase (green) was
specifically localized to the myenteric ganglion plexus of tamoxifen
treated NSE-MerCreMer/R26R double transgenic mice (Figure 7A,
C). Very weak or a complete absence of b-galactosidase immuno-
reactivity was detected at the myenteric ganglion plexus in the
corn oil treated double transgenic intestine from transgenic line
#778 (Figure 7B), and #805 (Figure 7D).
RT-PCR revealed weak to moderate expression of MerCreMer
transgene in some of the non-neural tissues from line #778 and
line #805 (Figure 3A), immuno-fluorescence staining for b-
galactosidase were performed on sections prepared from these
non-neural tissues of NSE-MerCreMer/R26R mice (both lines #778
and #805; tamoxifen and corn oil treated). No specific staining
could be detected in these non-neural tissues from either tamoxifen
or corn oil treated NSE-MerCreMer/R26R mice (data not shown).
In conclusion, we established transgenic mouse lines NSE-
MerCreMer that express tamoxifen inducible Cre activity, which
allow a temporal control of the Cre/loxP recombination event in
neurons. Our transgenic mice will be very useful in studying loss of
gene function (Cre-mediated gene deletion) and/or gain of gene
function (Cre-mediated gene expression) by Cre-mediated recom-
bination in neurons, which results in embryonic lethality and
precludes investigation of gene functions in neurons through later
stages of development and in adult. Furthermore, as a gene
expressed in neurons at different developmental stages may play
distinct roles, NSE-MerCreMer mice allow investigation of different
functions of a gene in neurons at different stages of nervous system
development, providing critical information on the pathogenesis of
neurodegeneration in normal aging and pathological conditions,
which has been obsessing many individuals and levying a heavy
burden to society.
Materials and Methods
Generation of Transgenic Construct NSE-MerCreMer
The 1.8 kb promoter of the rat neural specific enolase (NSE)
gene was subcloned from the NSE-Cre transgenic construct [16] 59
upstream of the cDNA encoding the MerCreMer protein [9]. The
insert of the transgenic construct NSE-MerCreMer was completely
sequenced to ascertain that no mutation was introduced during the
cloning steps.
Cell Culture and Transfection
HeLa cells were cultured in DMEM containing 10% fetal calf
serum (Clontech, CA, USA), 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate in
5% CO2 at 37uC. HeLa cells (3x10
5) were plated in each well of a
24-well tissue culture plate 24 hours before co-transfection with
NSE-MerCreMer construct and pCAG-CAT-LacZ plasmid (0.5 mg
each) using Lipofectamine 2000 (Invitrogen
TM) according to the
manufacturer’s protocol. Cre activity was induced by the addition
of 4-hydroxy-tamoxifen (4-OHT; 0.8 mM as final concentration)
to the culture and incubation for 27 hours. Cells were then fixed in
4% paraformaldehyde/PBS (PFA/PBS; 10 minutes, room tem-
perature), washed with PBS and stained for b-galactosidase activity
in X-gal staining solution containing 5 mM K3Fe(CN)6,5m M
K4(CN)6, 2 mM MgCl2, 0.01% Sodium deoxycholate, 0.02% NP-
40, 1 mg/ml X-gal in PBS at 37uC for 3 hours.
Generation of Transgenic Line
The DNA insert of NSE-MerCreMer construct was released by
NotI digestion, purified and micro-injected into fertilized oocytes
collected from super-ovulated (CBA/129) F1 hybrid mouse. The
micro-injected fertilized eggs were transferred to pseudo-pregnant
wild type ICR foster mothers. NSE-MerCreMer transgenic founder
mice were backcrossed to (CBA/129) F1 hybrid mice for germ-line
transmission to establish transgenic lines. All experimental
procedures were approved by the Committee on the Use of Live
Animals at the University of Hong Kong (approval CULTRA
1044-05).
Genotyping of Transgenic Mice
Genomic DNA was extracted from 2 mm tail clip using PBND
extraction method (http://www.jax.org/imr/tail_nonorg.html). In
brief, mouse-tail was digested with 40 mg Proteinase K (Invitro-
gen
TM) in 200 ml PBND buffer at 55uC for 16 hours. After heating
at 96uC for 10 minutes to inactivate the Proteinase K, the tail
digest was used as template DNA for PCR analysis. For the
detection of the MerCreMer transgene, the following primers were
used: CreF1 (59-CGT ACT GAC GGT GGG AGA AT-39) and
CreR1 (59-TGC ATG ATC TCC GGT ATT GA-39). PCR
reaction was performed in PCR buffer (25 ml) containing 0.2 mM
dNTP (Promega), forward and reverse primer (0.2 mM each),
template DNA (1 ml), DMSO (5%; v/v, Merck), MgCl2 (4 mM)
and 0.25 ml of Ampli Taq Gold
TM (Roche). Amplication was
performed as follows: initial denaturation: 94
oC for 7 minutes, 40
PCR cycles: 94uC; 30 seconds, 54uC; 30 seconds, 72uC; 30
seconds, final extension: 72
oC; 10 minutes. Amplification of NSE-
MerCreMer transgene generated a 374 bp DNA fragment.
Western Blot Analysis
Brain and small intestine were harvested from postnatal week-4
NSE-MerCreMer and non-transgenic mice, homogenized in 1 ml of
lysis buffer (Cell signaling) containing protease inhibitor (20 ml;
Roche), 1 mM DTT (USB) and 0.1 mM PMSF (USB) on ice. The
supernatant was collected by centrifugation (13,000 rpm, 15
minutes, 4
oC). Protein (30 mg) of each samples were separated
by electrophoresis in 8% (w/v) polyacrylamide gel, and were
electro-transferred onto PVDF membrane (Millipore). After
blocking in TBS-T (50 mM Tris-HCl, pH 7.6, 150 mM NaCl,
Tamoxifen Inducible Cre in Neurons
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the membrane was incubated with anti-ERa serum (1:100 dilution
in blocking solution; Ab-10; LabVision) for 16 hours at 4uC. After
TBS-T rinse (3615 minutes), and an incubation in HRP-
conjugated secondary antibody (1:5000 dilution; P0399; Dako; 1
hour, room temperature), the membrane was washed in TBS-T.
Signal was visualized by chemiluminescence (GE Health Amer-
sham ECL Plus Western Blotting Detection System) and exposure
to X-ray film (Kodak). For reprobing, membrane was stripped by
heating at 60uC for 30 minutes in 10 mM Tris-HCl pH 6.8; 2%
SDS (w/v); 100 mM 2-mercaptoethanol, followed by an incuba-
tion with anti-b-actin serum (1:5000; AC-74; Sigma) at room
temperature for 1 hour. After TBS-T rinse, signal was visualized
by ECL.
To detect the expression of b-galactosidase in the brain, spinal
cord and small intestine of NSE-MerCreMer mice upon tamoxifen
induction, protein of each samples from week-4 NSE-MerCreMer
mice (tamoxifen or corn oil treated; at least two mice were
analyzed from each line in each treatment groups) and Rosa26R
mice were prepared as described above. Samples from the week-4
Z/EG mice (Tg(ACTB-Bgeo/GFP)21Lbe/J; The Jackson Labo-
ratory) that expressed b-galactosidase constitutively were included
as a positive control. Protein (100 mg) of each samples were
separated by electrophoresis in 6% (w/v) polyacrylamide gel, and
were electro-transferred onto PVDF membrane. After blocking in
TBS-T with 5% non-fat milk (w/v) for 2.5 hours at room
temperature, the membrane was incubated with anti-b-galactosi-
dase serum (1:5000 dilution; ab616; Abcam) for 16 hours at 4uC.
After TBS-T rinse, and an incubation in HRP-conjugated
secondary antibody (1:5000 dilution; P0399; Dako; 1 hour, room
temperature), the membrane was washed in TBS-T. Signal was
visualized by chemiluminescence (GE Health Amersham ECL
Plus Western Blotting Detection System) and exposure to X-ray
film (Kodak). Membrane was stripped and reprobed with anti-b-
actin serum as described above.
Figure 6. Tamoxifen induction of b-galactosidase in neurons of the central nervous system. Coronal sections of the forebrain (A), rostral
(B) and caudal (C) midbrain, and cerebellum (D) of NSE-MerCreMer/R26R double transgenic mice of lines #778 and #805 fed with tamoxifen (TM) or
corn oil (CO) and Rosa26R (R26R) mice were analyzed by co-immunofluorescence staining for b-galactosidase (green) and NeuN (red). Superimposed
photos of immuno-fluorescence for b-galactosidase (green) and NeuN (red) showed co-localization of b-galactosidase and NeuN immuno-reactivity in
neurons in tamoxifen fed NSE-MerCreMer/R26R mice. Arrowheads indicated the Purkinje cells in the cortex of the cerebellum (D). Arrows indicated
that few neurons in the corn oil treated forebrain cerebral cortex expressed weak b-galactosidase (A). Dotted square indicated the plans of the
coronal sections being analyzed from different regions of the brain. The respective locations of the superimposed photos being taken from the
sections were indicated by letters on the drawing of the sections. At least two NSE-MerCreMer/R26R mice from each line were analyzed for each
treatment groups.
doi:10.1371/journal.pone.0035799.g006
Figure 7. Tamoxifen induction of Cre activity in neurons of the enteric nervous system. Intestine of NSE-MerCreMer/R26R double
transgenic mice of lines #778 and #805 fed with tamoxifen (A, C) or corn oil (B, D) were analyzed by immuno-fluorescence for b-galactosidase
(green). Dotted regions were magnified and shown as insets. Abbreviations: m, mucosa; cm, circular muscle; lm, longitudinal muscle.
doi:10.1371/journal.pone.0035799.g007
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Total RNA was isolated using TRIzol (Invitogen
TM) according
to manufacturer’s protocol. RNA (1 mg) was treated with RQ1
RNase-Free Dnase (Promega) to remove genomic DNA. First-
strand cDNA was synthesized according to the protocol provided
by the Reverse Transcription System (Promega). Transcript of
MerCreMer was detected by PCR using CreR1 and CreF1 primers
pair. PCR amplification for mouse b-actin using b-actin specific
primers: b-actinF1 (59-GAG AGG GAA ATC GTG CGT GAC-
39) and b-actinR1 (59-AGC TCA GTA ACA GTC CGC CTA-39)
was included as internal control to test the integrity of RNA. PCR
amplification was performed as follow: 94
oC for 7 minutes, 40
cycles of (94uC for 45 seconds, 55uC for 45 seconds, 72uC for 45
seconds), 72
oC for 10 minutes. Amplification of b-actin generated a
534 bp fragment.
Immuno-fluorescence
Brain and intestine were fixed in 4% PFA in PBS at 4
oC for
overnight. After PBS (Phosphate buffered saline pH 7.4) rinse, the
specimens were incubated in 10% sucrose solution for 1 hour at
4
oC and then 30% sucrose solution at 4
oC for 24 hours. The
specimens were embedded and frozen in O.C.T. (Tissue-Tek).
Transverse sections (6 mm in thickness) were prepared and
mounted onto microscopic glass slides coated with TESPA (3-
aminopropyl-triethoxysilane; Sigma). Antigen was retrieved by
incubating in 10 mM sodium citrate buffer (pH 6.0) at 95uC for 10
minutes. After blocking in PBS-T (PBS with 0.1% Triton)
supplemented with 10% normal goat serum (Dako) for 1 hour at
room temperature, sections were incubated with either anti-b-
galactosidase (1:200; ab8361; Abcam) plus anti-NeuN (1:100;
MAB377; Chemicon) or anti-ERa (1:100; Ab-10; LabVision) plus
anti-Tuj1 (1:500; MMS-435P; Covance) in PBS-T for overnight at
4
oC. The sections were washed in PBS-T and incubated with
appropriate fluorochrome conjugated secondary antibody (1:200;
Invitrogen
TM) at room temperature for 2 hours. After PBS-T
wash, sections were mounted in DAPI containing anti-fade
solution (Vector Laboratories., Inc.). Images were taken with
Nikon Eclipse 80i microscope mounted with SPOT RT3
microscope digital camera (DIAGNOSTIC instruments, Inc.),
and photos were compiled using Adobe Photoshop 7.
Tamoxifen Induction
Tamoxifen stock (20 mg/ml of corn oil) was prepared by
warming tamoxifen (Sigma) in corn oil at 65
oC (protected from
light) until completely dissolved. Tamoxifen (0.15 mg per gram of
body weight for four consecutive days) was administered by
intragastric gavage to adult mice. For control, corn oil was given
instead of tamoxifen.
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